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The KCL039 human embryonic stem cell linewas derived from a normal healthy blastocyst donated for research.
The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Resource table
Resource details
Stem Cell Research 16 (2016) 170–172
⁎ Corresponding author.
E-mail address: dusko.ilic@kcl.ac.uk (D. Ilic).
Name of stem
cell line
KCL039
Institution King's College London, London UK
Derivation team Neli Kadeva, Victoria Wood, Glenda Cornwell,
Stefano Codognotto, Emma Stephenson
Contact person
and email
Dusko Ilic, email: dusko.ilic@kcl.ac.uk
Date archived/
stock date
Feb. 03, 2012
Type of resource Biological reagent: cell line
Sub-type Human pluripotent stem cell line
Origin Human embryo
Key marker
expression
Pluripotent stem cell markers: NANOG, OCT4, TRA-1-60,
TRA-1-81, alkaline phosphatase (AP) activity
Authentication Identity and purity of line conﬁrmed
Link to related
literature
(direct URL
links and full
references)
1) Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J.,
Al-Bedaery, R., Renwick, P., Ogilvie, C., Vaughan, R., Ilic, D.,
2013. Strategy for the creation of clinical grade hESC line
banks that HLA-match a target population. EMBO Mol.
Med. 5 (1), 10–17.
doi: 10.1002/emmm.201201973
http://www.ncbi.nlm.nih.gov/pubmed/23161805
2) Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P.,
Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J.,
Moore, H.D., Murray, H., Kunath, T., 2015. The molecular
karyotype of 25 clinical-grade human embryonic stem
cells lines. Sci. Rep. 5, 17258.
doi: 10.1038/srep17258
http://www.ncbi.nlm.nih.gov/pubmed/26607962
3) Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D.,
Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple,
M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation
and feeder-free propagation of human embryonic stem
cells under xeno-free conditions. Cytotherapy. 14 (1),
122–128.
doi: 10.3109/14653249.2011.623692
http://www.ncbi.nlm.nih.gov/pubmed/22029654
4) Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N.,
Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D.,
2012. Derivation and propagation of human embryonic
stem cell lines from frozen embryos in an animal
product-free environment. Nat. Protoc. 7 (7), 1366–1381.
doi: 10.1038/nprot.2012.080
http://www.ncbi.nlm.nih.gov/pubmed/22722371
Information
in public
databases
KCL039 is a National Institutes of Health (NIH) registered hESC
line
NIH Registration Number: NIHhESC-14-0274
http://grants.nih.gov/stem_cells/registry/current.htm?id=680
Ethics The hESC line KCL039 is derived under license from the UK
Human Fertilisation and Embryology Authority (research
license numbers: R0075 and R0133) and also has local
ethical approval (UK National Health Service Research Ethics
Committee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the
experiments conformed to the principles set out in the
WMA Declaration of Helsinki and the NIH Belmont Report.
No ﬁnancial inducements are offered for donation.
(continued)
Consent signed Nov. 15, 2011
Embryo thawed Jan. 16, 2012
UK Stem Cell Bank
Deposit Approval
Reference: SCSC12-37
Sex Male 46, XY
Grade Clinical
Disease status Healthy/Unaffected
Karyotype (aCGH) No copy number changes detected
http://dx.doi.org/10.1016/j.scr.2015.12.036
1873-5061/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scr
We generated a KCL039 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after a freeze/thaw cycle (Fig. 1). Differentiation
potential into three germ layers was veriﬁed in vitro (Fig. 2).
The embryo donors were negative for Human Immunodeﬁciency
Virus 1/2 (HIV1/2), Hepatitis B (HepB, HCB) and C Virus (HepC, HCV).
We did not retest the line.
We also generated a research grade of the KCL039 line that is
adapted to feeder-free conditions.
Materials and methods
Consenting process
We distributed patient information sheets (PIS) and consent forms
to the in vitro fertilization (IVF) patients if they opted to donate to
research embryos that were stored for 5 or 10 years. They mail signed
consent back to us and that might be months after the PIS and consent
forms were mailed to them. If in the meantime new versions of PIS/
consent forms are implemented, we do not send these to the patients
or ask them to re-sign; the whole process is done with the version that
was given them initially. The PIS/consent documents (FRO-V.10) were
created on Sep. 19, 2011. The HFEA Code of Practice that was in effect at
the time of document creation was: Edition 8 — R.3 (http://www.hfea.
gov.uk/2999.html). The donor couple signed the consent on Nov. 15,
2011. TheHFEACodeof Practice thatwas in effect at the timeof donor sig-
nature was: Edition 8 — R.4. The HFEA Code of Practice Edition 8 — R.3
was in effect from Apr. 07, 2011 to Oct. 01, 2011, whereas 8 — R.4 was
in effect from Oct. 02, 2011 to Apr. 02, 2012.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as previous-
ly described (Ilic et al., 2012; Stephenson et al., 2012). Trophectoderm
cells were removed mechanically from outgrowth (Ilic et al., 2007; Ilic
et al., 2010). hESC colonies were expanded and cryopreserved at the
third passage.
Viability test
Straws with the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere partly frozen andpartly subject-
ed to a standard battery of tests (pluripotency markers, in vitro and
in vivo differentiation capability, genetics, sterility, and mycoplasma).
Fig. 1. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
ﬁbers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.
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SNP array No structural genomic variants detected (Canham
et al., 2015)
DNA ﬁngerprint Allele sizes (in bp) of 16 microsatellite markers
speciﬁc for chromosomes 13, 18 and 21 (Jacquet et al.,
2013)
HLA typing HLA-A 01, 24; B 35, 49; Bw 4, 6; C 04, 07; DRB1 03;
DRB3 01/02; DQB1 02 (Jacquet et al., 2013; Canham
et al., 2015)
Viability testing Pass
Mycoplasma Negative
Sterility Pass
Pluripotent markers
(immunostaining)
(Fig. 1)
NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
Three germ layers
differentiation in vitro
(immunostaining)
(Fig. 2)
Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)
Sibling lines available No
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Pluripotency
Pluripotency in vitro was assessed using two different techniques:
enzymatic activity assay [alkaline phosphatase (AP) assay] and immu-
nostaining as previously described (Ilic et al., 2012; Stephenson et al.,
2012).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro as previously described (Petrova et al., 2014; Stephenson et al.,
2012).
Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA ex-
traction robot according to themanufacturer's instructions. Ampliﬁcation
of polymorphic microsatellite markers was carried out as previously
described (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
Array comparative genomic hybridization (aCGH)
aCGH was performed as described in detail by Ilic et al. (2012).
Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in detail by Canham et al.
(2015).
HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as previously described (Jacquet
et al., 2013). HLA typing was also performed independently by another
group (Canham et al., 2015).
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Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
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